Chemistry:Marimastat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C15H29N3O5 |
| Molar mass | 331.413 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.[1][2]
Marimastat performed poorly in clinical trials,[3] and development was terminated.[citation needed] This may be, however, a result of targeting cancer at too late of a stage. This is supported by the fact that MMP inhibitors have more recently been shown in animal models to be more effective in earlier stages of cancers. (Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. (1999)).
See also
References
- ↑ "Marimastat". National Cancer Institute. http://www.cancer.gov/drugdictionary/?CdrID=42443.
- ↑ "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". British Journal of Clinical Pharmacology 45 (1): 21–6. January 1998. doi:10.1046/j.1365-2125.1998.00639.x. PMID 9489589.
- ↑ "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". Journal of Clinical Oncology 22 (23): 4683–90. December 2004. doi:10.1200/JCO.2004.08.054. PMID 15570070.
 |  |
